<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prognosis for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> with hypomethylating treatment failure (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-HTF) has been known to be poor </plain></SENT>
<SENT sid="1" pm="."><plain>However, the clinical outcomes and optimal treatment options for <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> evolving from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-HTF (sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-HTF) are not well known </plain></SENT>
<SENT sid="2" pm="."><plain>This retrospective analysis was conducted to evaluate the clinical outcomes and influences of treatment options on survival in 46 consecutive patients with sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-HTF </plain></SENT>
<SENT sid="3" pm="."><plain>The median OS rates were 1.4 months in the best supportive care group (n=15) and 9.4 months in the active treatment group (n=31) </plain></SENT>
<SENT sid="4" pm="."><plain>One-year OS rates were 13.3% and 36.8%, respectively (P=0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Active treatment (P&lt;0.001), lower BM blast (&lt;33%) at sAML (P=0.007), non-poor <z:chebi fb="0" ids="29819">NCCN </z:chebi>(National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Comprehensive Network) cytogenetics (P=0.001) and good performance status (ECOG (Eastern Cooperative <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group) î‹º1) (P=0.024) were significant predictors affecting favorable OS in a multivariate analysis </plain></SENT>
<SENT sid="6" pm="."><plain>Of the active treatment options, allo-SCT with prior chemotherapy (CTx) showed better OS compared with CTx only or SCT without CTx (P=0.019) </plain></SENT>
<SENT sid="7" pm="."><plain>Our analyses suggest that active treatment, particularly SCT following CTx, should be considered in patients with sAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-HTF if the patient is medically fit </plain></SENT>
</text></document>